WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc. (TMO) announced today that it has priced an offering of €500 million aggregate principal amount of 1.450% senior notes due 2027 at an issue price of 98.824% of the principal amount.
The issuance of the notes is expected to close on or about March 16, 2017, subject to customary closing conditions. The notes will pay interest on an annual basis.
Thermo Fisher intends to use approximately $508 million of the net proceeds of the offering to redeem all of the outstanding $500 million aggregate principal amount of its 1.850% senior notes that mature on January 15, 2018 and to pay accrued interest, fees and expenses associated with the redemption. Thermo Fisher intends to use any remaining net proceeds for general corporate purposes.
The joint book-running managers for the offering are Credit Suisse Securities (Europe) Limited and HSBC Bank plc.
The offering is being made pursuant to an effective registration statement on Form S-3, as amended by the post-effective amendment thereto (including a prospectus), filed with the U.S. Securities and Exchange Commission (the “SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling Credit Suisse Securities (Europe) Limited toll-free at 1-800-221-1037, or by calling HSBC Bank plc toll-free at 1-866-811-8049.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the company’s intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and prospectus supplement dated March 7, 2017 related to the offering, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings,” and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.